P110beta-targeted peptide inhibitor for PI3K-driven cancers
This technology involves engineered peptides — small, specially designed protein fragments — that are built to home in on a specific enzyme called PI3K (particularly the p110beta subunit), which acts as a key driver in certain cancers and other diseases. The peptides are paired with a delivery mechanism that helps them get inside cells where PI3K operates. By blocking or modulating PI3K activity, these peptides could slow or stop disease progression. The approach targets a well-validated cancer pathway using a biological rather than small-molecule strategy, which may offer selectivity advantages over existing drugs.
What you could build
A pipeline therapeutic candidate — an injectable or infusible peptide drug — targeting PI3K-driven cancers such as breast, prostate, or glioblastoma; primary buyers would be biotech or pharma companies licensing early-stage oncology assets for IND-enabling development.
Who in Virginia should care
Virginia-based biotech startups, NCI-affiliated researchers at Inova or UVA Health, or mid-size pharma business development teams scouting oncology pipeline assets in the Mid-Atlantic region.
Readiness: Concept
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Robert G. Gourdie, Zhi Sheng, Kevin J. Pridham, Linda Jane Jourdan
- Filed
- Patent pending — filed April 4, 2023
- Status
- Application
- Publication number
- US20240075093A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology. Email us for an introduction prosim@harbor.capital.
Prosim summaries are generated from public patent text and are not legal advice.